Tradestie Institutional Equity Comparison Engine

INSM vs REGN โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-19 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

REGN Overall Edge

REGN Captures Institutional Edge (4โ€“0 Pillars ยท 9โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Regeneron Pharmaceuticals Inc (REGN) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, INSM trades at N/M Forward P/E with -41.7% operating margin (+268.4% YoY revenue) versus REGN at 14.9x Forward P/E and 30.4% operating margin (+36.3% YoY). In options structure, INSM sits in CONSOLIDATION (38th %ile IV; Dealer Gamma Walls on Pro) against REGN sits in CONSOLIDATION (6th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner REGN
INSM N/M vs REGN 14.9x Fwd P/E
Growth & Margin Winner REGN
Op Margin -41.7% vs 30.4% ยท YoY +268.4% vs +36.3%
Momentum & Technical Winner REGN
1Y -28.4% vs +27.3% ยท 52W Pos 44% vs 83%
Options & Structure Winner REGN
CONSOLIDATION (38th %ile IV) vs CONSOLIDATION (6th %ile IV)
INSM NASDAQ
Insmed, Inc.
Pharmaceutical Preparations
$144.46
+20.58% 1D
Market Cap $26.3B
1M Return +53.62%
1Y Return -28.35%
Forward P/E N/M
Unified AI Score
35.9 / 100 SELL
Tech 5.0 Fund 35.0 Flow 66.0 Mom 40.0
REGN NASDAQ
Regeneron Pharmaceuticals Inc
Pharmaceutical Preparations
$923.34
-2.35% 1D
Market Cap $97.8B
1M Return +14.61%
1Y Return +27.3%
Forward P/E 14.9x
Unified AI Score
45.1 / 100 HOLD
Tech 28.0 Fund 45.0 Flow 68.0 Mom 56.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: INSM -28.35% REGN +27.3% Spread: +55.65 pp (REGN Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period INSM Revenue REGN Revenue INSM Op. Margin REGN Op. Margin Margin Edge
FY2018 $10M $5.15B -3124.9% 49.3% REGN
FY2019 $140M $6.56B -172.4% 33.7% REGN
FY2020 $160M $8.50B -161.3% 42.1% REGN
FY2021 $190M $16.1B -199.0% 55.7% REGN
FY2022 $250M $12.2B -186.4% 38.9% REGN
FY2023 $310M $13.1B -232.5% 30.9% REGN
FY2024 $360M $14.2B -241.5% 28.1% REGN
FY2025 $610M $14.3B -205.6% 24.9% REGN

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: INSM (1) vs REGN (9)
Institutional Metric INSM REGN Criterion Row Winner
Market Capitalization Scale $26.3B $97.8B Larger Scale REGN
Trailing P/E Ratio Valuation 107.5x 20.9x Lower Multiple REGN
Forward P/E Ratio Valuation N/M 14.9x Lower Multiple REGN
Revenue Growth (YoY) Growth +268.4% +36.3% Higher Growth INSM
Operating Margin (TTM) Profitability -41.7% 30.4% Higher Margin REGN
Net Profit Margin Profitability -39.9% 28.5% Higher Margin REGN
Return on Equity (ROE) Capital Efficiency -72.5% 14.9% Higher ROE REGN
52-Week Range Position Momentum 44% ($90โ€“$213) 83% ($592โ€“$992) Stronger Trend REGN
Beta / 30D Volatility Risk Regime 0.40ฮฒ ยท 90% Vol 0.32ฮฒ ยท 55% Vol Lower Realized Risk REGN
Unified Institutional Score Composite Signal 35.9 / 100 (SELL) 45.1 / 100 (HOLD) Higher Composite REGN

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full INSM vs REGN Buy Guide
INSM CONSOLIDATION
72d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 38th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live INSM Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
REGN CONSOLIDATION
55d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 6th %ile
IV Regime Compressed (<25th %ile)
Live REGN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither INSM nor REGN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.